Shilpa Medicare Ltd gets US approval for Varenicline Tablets, 0.5 mg and 1 mg

Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, has received approval from USFDA for Varenicline Tablets, 0.5 and 1 mg.

The total US market for this product is around 203 M USD.

Shilpa's product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism).

Varenicline Tablets are indicated for smoking cessation; it helps people to quit smoking.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 609.45 as compared to the previous close of Rs. 643.55. The total number of shares traded during the day was 11450 in over 1082 trades.

The stock hit an intraday high of Rs. 630.95 and intraday low of 606.90. The net turnover during the day was Rs. 7106126.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 Pharmaceuticals USFDA Approval VareniclineTablets